BCL11A and Schnyder corneal dystrophy: In conclusion, this study provides insights into the applicability of multiplexed base editing strategies to treat SCD and potentially β-thalassemia patients through disruption of the erythroid-specific BCL11A enhancers in the +58-kb and +55-kb regions.